July 3, 2025 07:00 AM EDTUpdated 02:00 PM
Peer Review

Now pri­vate, blue­bird bio con­tin­ues lead­er­ship re­vamp; Roche R&D ex­ec an­nounces re­tire­ment

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Lei Lei Wu

News Reporter

Blue­bird bio rolled out three new ex­ec­u­tive hires on Tues­day: Bri­an Ri­ley as pres­i­dent and chief tech­ni­cal of­fi­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: FDA pub­lish­es repos­i­to­ry of 200+ drug re­jec­tion let­ters, promis­ing more in the fu­ture

FDA hands Capri­cor a CRL for its Duchenne cell ther­a­py 

Biotech’s Q2 num­bers paint a pic­ture of the good, the bad and the ug­ly

Ab­b­Vie inks $700M deal with IGI for mul­ti­ple myelo­ma trispe­cif­ic an­ti­body

Cen­tu­ry Ther­a­peu­tics lays off half of its staff, CFO de­parts as it nar­rows pri­or­i­ties

sponsored

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

A service from the Financial Times